MX2007002271A - Terapia anticancer combinada y composiciones farmaceuticas para la misma. - Google Patents

Terapia anticancer combinada y composiciones farmaceuticas para la misma.

Info

Publication number
MX2007002271A
MX2007002271A MX2007002271A MX2007002271A MX2007002271A MX 2007002271 A MX2007002271 A MX 2007002271A MX 2007002271 A MX2007002271 A MX 2007002271A MX 2007002271 A MX2007002271 A MX 2007002271A MX 2007002271 A MX2007002271 A MX 2007002271A
Authority
MX
Mexico
Prior art keywords
relates
pharmaceutical compositions
anticancer therapy
cancer
general formula
Prior art date
Application number
MX2007002271A
Other languages
English (en)
Inventor
Jacques Alain Bauer
Carlo Chiavaroli
Original Assignee
Om Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Om Pharma filed Critical Om Pharma
Publication of MX2007002271A publication Critical patent/MX2007002271A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Esta invencion se relaciona con la terapia anticancer, y de manera mas precisa, con el control inmunologico del cancer. Especificamente esta invencion se relaciona con composiciones farmaceuticas que incorporan como el agente activo al menos un agente inmunoestimulante con grupos cargados o centrales de formula general (I), donde X, Y, A, B, R1 y R2 son como se definen en la especificacion junto con un metodo de radioterapia adecuado para combatir el cancer o junto con un agente quimioterapeutico seleccionado del grupo que consiste de agentes alquilante, agentes antimetabolicos, agentes que actuan sobre los tumulos e inhibidores de tirosina Cinasa en conjunto o en mezcla con un diluente o soporte farmaceuticamente aceptable no toxico. Esta invencion tambien se relaciona con las sales de un compuesto de formula general (I) con una base mineral u organica, es decir una base farmaceuticamente aceptable. El uso para tratar condiciones cancerosas dentro de un solo recipiente o contenido dentro de distintos recipientes.
MX2007002271A 2004-07-23 2005-03-10 Terapia anticancer combinada y composiciones farmaceuticas para la misma. MX2007002271A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IB2004002378 2004-07-23
PCT/IB2005/000944 WO2006011007A1 (en) 2004-07-23 2005-03-10 Combination anticancer therapy and pharmaceutical compositions therefore

Publications (1)

Publication Number Publication Date
MX2007002271A true MX2007002271A (es) 2007-06-15

Family

ID=34958692

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2007002271A MX2007002271A (es) 2004-07-23 2005-03-10 Terapia anticancer combinada y composiciones farmaceuticas para la misma.

Country Status (10)

Country Link
US (1) US20090214669A1 (es)
EP (2) EP1773318A1 (es)
JP (1) JP2008507499A (es)
KR (1) KR20070065311A (es)
AU (1) AU2005266106B2 (es)
CA (1) CA2587019A1 (es)
MX (1) MX2007002271A (es)
RU (1) RU2396960C2 (es)
WO (1) WO2006011007A1 (es)
ZA (1) ZA200701578B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005266106B2 (en) * 2004-07-23 2010-12-09 Om Pharma Combination anticancer therapy and pharmaceutical compositions therefore
KR101726282B1 (ko) * 2008-08-15 2017-04-12 더 유에이비 리서치 파운데이션 뉴클레오시드 프로드럭의 효소 활성자로서의 퓨린 뉴클레오시드 인산화효소
US8114845B2 (en) * 2008-08-25 2012-02-14 Amplimmune, Inc. Compositions of PD-1 antagonists and methods of use
US8357652B2 (en) 2009-11-20 2013-01-22 Academia Sinica Anti-tumor fibrillar human serum albumin methods and compositions
UA98666C2 (ru) * 2010-03-25 2012-06-11 Геннадий Васильевич Мазильников Лекарственный препарат на основе щавелевой кислоты, проявляющий противоопухолевое действие в отношении злокачественных клеток, и способ лечения
UA98665C2 (ru) * 2010-03-25 2012-06-11 Геннадий Васильевич Мазильников Лекарственный препарат, проявляющий противоопухолевое действие в отношении злокачественных клеток, и способ лечения
US10585101B2 (en) * 2016-03-10 2020-03-10 Wavesense, Inc. Prostatic liquid biopsy for the detection of prostate cancer and benign prostatic hyperplasia

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3443507A1 (de) * 1984-11-29 1986-06-12 Mückter, Heinrich, Dipl.-Chem. Dr., 5100 Aachen Verwendung von gereinigten lipopolysacchariden und deren derivaten
EP0668289A4 (en) * 1993-09-07 1998-10-21 Suntory Ltd NEW DISACCHARIDE DERIVATIVE.
ATE195740T1 (de) * 1993-11-17 2000-09-15 Om Pharma Glucosamin-disaccharide, verfahren zu deren herstellung, pharmazeutische präparate davon und ihre verwendung
AU1581400A (en) * 1999-12-22 2001-07-03 Om Pharma Acyl pseudopeptides bearing a functionalised auxiliary spacer
US20020156033A1 (en) * 2000-03-03 2002-10-24 Bratzler Robert L. Immunostimulatory nucleic acids and cancer medicament combination therapy for the treatment of cancer
WO2003079299A2 (en) * 2002-03-18 2003-09-25 Koninklijke Philips Electronics N.V. Holder for papers of value, and method of registering the contents thereof
AU2005266106B2 (en) * 2004-07-23 2010-12-09 Om Pharma Combination anticancer therapy and pharmaceutical compositions therefore

Also Published As

Publication number Publication date
RU2007106845A (ru) 2008-09-10
RU2396960C2 (ru) 2010-08-20
KR20070065311A (ko) 2007-06-22
ZA200701578B (en) 2008-09-25
JP2008507499A (ja) 2008-03-13
WO2006011007A1 (en) 2006-02-02
US20090214669A1 (en) 2009-08-27
AU2005266106B2 (en) 2010-12-09
AU2005266106A1 (en) 2006-02-02
CA2587019A1 (en) 2006-02-02
EP2170318A1 (en) 2010-04-07
EP1773318A1 (en) 2007-04-18

Similar Documents

Publication Publication Date Title
MX2007002271A (es) Terapia anticancer combinada y composiciones farmaceuticas para la misma.
UA83091C2 (en) Pyrido[2,3-d]pyrimidine-2,4-diamines as pde 2 inhibitors
AU2001252609A1 (en) Imidazopyridine derivatives
MY141739A (en) Substituted quinazoline derivatives as inhibitors of aurora kinases
MY189118A (en) Pyrazolo[1,5-a]pyrazin-4-yl derivatives
RS20050522A (en) Protein kinase inhibiting tricyclic compounds that increase the effects of anti-neoplastic agents and therapeutic radiation
EP1631548A4 (en) INHIBITORS OF AKT ACTIVITY
WO2004096131A3 (en) Inhibitors of akt activity
TR200102911T2 (tr) Adamantan türevleri.
WO2004113335A3 (en) Pyridino[1,2-a]pyrimidin-4-one compounds as anticancer agents
CA2480800A1 (en) Inhibitors of akt activity
HUP0303271A2 (hu) Rapamycin felhasználása rák kezelésére alkalmas gyógyszerkészítmény elõállítására
TW200517106A (en) Sustained release pharmaceutical compositions
UA90285C2 (ru) Производные гидантоина, полезные как ингибиторы металлопротеиназ
AU2003228770A1 (en) Substituted pyrazolopyrimidines
MXPA05008690A (es) Derivados de adamantano, procedimientos para su preparacion y composiciones farmaceuticas que los contienen.
RS84904A (en) Combined use of antitumor indolopyrrolocarbazole derivative and other antitumor agent
WO2007120333A3 (en) Tetracyclic kinase inhibitors
EP4108242A4 (en) PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER CONTAINING A MTOR SIGNALING INHIBITOR AS ACTIVE INGREDIENT
MXPA04004606A (es) Venenos de topoisomerasa solubilizados.
MX2021014680A (es) Derivado de benzotriazol.
TW200719899A (en) Tricyclic azole derivatives, their manufacture and use as pharmaceutical agents
MY162231A (en) Prophylactic device carrying a microbiocidal composition
AU2002364953A8 (en) Topoisomerase poison agents
EP1453507A4 (en) AGENTS POISONS OF SOLUBILIZED TOPOISOMERASES

Legal Events

Date Code Title Description
FG Grant or registration